Clinical Trials Logo

Filter by:
NCT ID: NCT03843606 Completed - McArdle Disease Clinical Trials

Modified Ketogenic Diet in Patients With McArdle Disease Part A

Start date: February 16, 2019
Phase: N/A
Study type: Interventional

McArdle disease, glycogen storage disease type V, is a rare metabolic disease. Affected individuals are unable to utilize sugar stored as glycogen in muscle. We hypothesize that a modified ketogenic diet could be a potential treatment option, by providing ketones as alternative fuel substrates for working muscle. In this open interventional pilot study we wish to investigate 3 different modified ketogenic diet regimes, to find an optimal composition of a modified ketogenic diet that ensures adequate degree of ketosis and at the same time is well tolerated for patients with McArdle disease.

NCT ID: NCT03843112 Completed - Infertility, Female Clinical Trials

Modulating the Vaginal Microbiome After Implantation Failure

Start date: March 1, 2019
Phase: Phase 4
Study type: Interventional

Vaginal microbiome has in studies shown a link with the outcome of fertility treatment. The investigators wish to determine if it is possible to change an unfavorable vaginal microbiome using lactobacilli loaded vaginal supplements.

NCT ID: NCT03837756 Completed - HIV-1-infection Clinical Trials

Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV

TITAN
Start date: May 6, 2019
Phase: Phase 2
Study type: Interventional

This study is designed to evaluate the safety and efficacy of lefitolimod and 3BNC117/10-1074 in HIV-1-infected individuals on ART and during ATI as intervention to reduce the HIV-1 reservoir

NCT ID: NCT03832972 Completed - Performance Clinical Trials

Performance During Menstrual Cycle

Start date: October 1, 2018
Phase:
Study type: Observational

This project aims to investigate if muscle strength and muscle power fluctuate during the menstrual cycle. The hypothesis is that the greatest performance will be measured right before ovulation, and at it's lowest on day 1 and 2 of the menstrual cycle in women not using any form for hormonal protection. And that the performance in women using birth control pills, not will variated in the period where they are taking pills (day 1-21).

NCT ID: NCT03832036 Completed - Pain Clinical Trials

The Diagnostic and Prognostic Value of Two Quantitative Clinical Tests in Patients With Lumbar Disc Herniation

Start date: October 1, 2018
Phase: N/A
Study type: Interventional

This study will investigate whether two clinical tests can be used to diagnose and predict the outcome in patients with lumbar disc herniation undergoing surgery and non-surgery treatment. The two quantitative clinical tests include: electromyographic measurements using Paraspinal Mapping and pain responses using Quantitative Sensory Pain Testing.

NCT ID: NCT03830983 Completed - Stroke Clinical Trials

Atrial Cardiomyopathy in Patients With Stroke of Undetected Mechanism

Start date: March 8, 2019
Phase:
Study type: Observational

The goal of this study is to evaluate left atrial structural and functional abnormalities in stroke of undetected mechanism and atherosclerotic stroke with cardiac MRI.

NCT ID: NCT03829995 Completed - Drug Counseling Clinical Trials

Effect of Pharmacist Provided Drug Information Services After Hospital Discharge

Start date: July 12, 2018
Phase: N/A
Study type: Interventional

Objective: The aim of this study is to evaluate if offering drug counseling from a hospital pharmacy increases patient satisfaction and sense of security regarding drug treatment after hospital discharge.

NCT ID: NCT03828240 Completed - Hip Fractures Clinical Trials

HIP Fracture REhabilitation Programme for Elderly With Hip Fractures

HIP-REP
Start date: February 1, 2019
Phase: N/A
Study type: Interventional

Objectives: To evaluate the feasibility of a HIP fracture REhabilitation Programme (HIP-REP).This study will investigate adherence, satisfaction, technical and practical circumstances regarding implementation and taking this into account when evaluating the feasibility of the HIP-REP program. Hypothesis: By testing the feasibility of a HIP-REP for the participants and the usefulness of the selected measurement tools, the investigators will be able to evaluate and adjust the HIP-REP before evaluating this in a larger Randomized controlled trial (RCT).

NCT ID: NCT03826381 Completed - Clinical trials for Chronic Kidney Diseases

NAFLD Among Patients With Type 2 Diabetes and CKD

Start date: May 6, 2019
Phase:
Study type: Observational

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in developed countries affecting approximately 30 % of the general adult population. It represents an important pathogenic factor in the development of type 2-diabetes and is associated with a high risk of cardiovascular disease. Previous studies of patients with chronic kidney disease (CKD) have demonstrated an increased risk for NAFLD and the presence of both CKD and NAFLD is likely to increase the risk for cardiovascular disease. The present protocol describes a study of the prevalence and etiology of NAFLD among patients with type 2-diabetes with CKD. The study is a cross-sectional study. Fat accumulation in the liver will be determined by Magnetic resonance (MR) spectroscopy and the prevalence of NAFLD among patients with type 2-diabetes with normal kidney function or CKD stage 3-5 will be investigated. A continuous glucose monitoring (CGM) for four days, Dual Energy X-ray Absorptiometry (DEXA) scanning, fibro scanning of the liver, bile acid analysis, metabolomic and lipidomic analysis will also be performed.

NCT ID: NCT03823300 Completed - Clinical trials for Wet Macular Degeneration

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)

Start date: March 11, 2019
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with neovascular age-related macular degeneration (nAMD).